Abstract:Abstract 58 Background: In 2011, an international panel of breast cancer experts developed the first Advanced Breast Cancer (ABC) Consensus Guidelines to provide standards and improved care for the multidisciplinary care of patients with this common disease. We sought to adapt the ABC guidelines for China, incorporating cultural standards and available Chinese resource, and identifying suitable formed guideline. Methods: We organized the Chinese Consensus Guidelines Conference for ABC (CABC) yearly from 2013 through 2015 in Beijing as a joint effort between the China Medical Women's Association, the Organization of Beijing Sunshine Great Wall Oncology Program, Peking University, The panel included 50 breast oncology and surgery experts from 20 provinces, as well as two external consultant oncologists from the U.S. and Singapore. Permission was obtained from the ABC Chair to use the guidelines as a basis for our discussion. All questions were presented and discussed in detail, including a review of current applicable data, and panel members voted on each question. Results: The main issues discussed included; 1. In China the patient treatment decision making generally by family members. 2. Use of sequential single agent chemotherapy for standard risk in China most experts still prefer combination therapy. 3. The trastuzumab are not covered by health insurance in China and/or pertuzumab is not yet available. 5. For hormone receptor positive ABC, some physicians in China prefer to start with chemotherapy . 7. Not well accepted by Chinese patients. Details of final voting and Chinese consensus will be presented. Conclusions: Standard guidelines are critical, but must be tailored to be used effectively in specific countries. The CABC has effectively discussed, modified and distributed guidelines for the treatment of ABC in China. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: Huiping Li No relationship to disclose Hope S. Rugo Honoraria: Genomic Health Speakers' Bureau: Genomic Health Research Funding: Plexxikon, Macrogenics, OBI Pharma, Eisai, Pfizer, Novartis, Eli Lilly, GlaxoSmithKline, Genentech, Celsion, Nektar, Merck, Amgen Travel, Accommodations, Expenses: Novartis, Nektar, Roche/Genentech, OBI Pharma, Mylan Jin Zhang No relationship to disclose Zhimin Shao No relationship to disclose Zhenzhou Shen No relationship to disclose Binhe Xu No relationship to disclose Jiong Wu No relationship to disclose Zefei Jiang No relationship to disclose Erwei Song No relationship to disclose Yinhua Liu No relationship to disclose Xichun Hu No relationship to disclose Cuizhi Geng No relationship to disclose Bo Li No relationship to disclose Jinhai Tang No relationship to disclose Jifeng Feng No relationship to disclose Pin Zhang No relationship to disclose Junlan Yang No relationship to disclose Qingyuan Zhang No relationship to disclose Jian Liu No relationship to disclose Yuee Teng No relationship to disclose Yongsheng Wang No relationship to disclose Zhongsheng Tong No relationship to disclose Guohong Song No relationship to disclose Peng Yuan No relationship to disclose Hongmei Zhao No relationship to disclose Wuyun Su No relationship to disclose Tao Sun No relationship to disclose Seng-Weng Wong Consulting or Advisory Role: MSD Oncology, Novartis, Roche, Pfizer Speakers' Bureau: MSD Oncology, Bayer, Novartis Travel, Accommodations, Expenses: Bayer, Roche, Merck Serono, Boehringer Ingelheim Yanshen Lu No relationship to disclose Yongchang Zhou No relationship to disclose

China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

CACA guidelines for holistic integrative management of adult acute myeloid leukemia

CACA Guidelines for Holistic Integrative Management of Nasopharyngeal Carcinoma

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

CACA guidelines for holistic integrative management of rectal cancer

A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]

Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Malignant Lymphoma 2021 (english Version)

Comments on Chinese Guidelines for Diagnosis and Treatment of Malignant Lymphoma 2018 (english Version).

[Chinese expert consensus on the diagnosis and management of elderly patients with follicular lymphoma (2024)]

Interpreting Advanced Breast Cancer Consensus Guidelines for Use in China

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

China Anti-Cancer Association Guidelines for the Diagnosis, Treatment, and Follow-Up of Thymic Epithelial Tumors (2023)

Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

CACA guidelines for holistic integrative management of prostate cancer

The interpretation of the Chinese Society of Clinical Oncology clinical guidelines for the diagnosis and treatment of diffuse large B-cell lymphoma